Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe

A. Sarah Walker, Andrew J. Prendergast, Peter Mugyenyi, Paula Munderi, James Hakim, Addy Kekitiinwa, Elly Katabira, Charles F. Gilks, Cissy Kityo, Patricia Nahiry-Ntege, Kusum Nathoo, and Diana M. Gibb; for the DART and ARROW trial teams

1MRC Clinical Trials Unit, London, 2Queen Mary University of London, United Kingdom, 3Joint Clinical Research Centre, Kampala, 4MRC/UVRI Uganda Research Unit on AIDS, Entebbe, 5University of Zimbabwe Clinical Research Centre, Harare, 6Baylor-Uganda Pediatric Infectious Disease Centre, Mulago, 7Infectious Disease Institute, Makere University, Kampala, Uganda, 8Imperial College, London, United Kingdom, and 9University of Zimbabwe Medical School, Harare

Background. Adult mortality in the first 3 months on antiretroviral therapy (ART) is higher in low-income than in high-income countries, with more similar mortality after 6 months. However, the specific patterns of changing risk and causes of death have rarely been investigated in adults, nor compared with children in low-income countries.

Methods. We used flexible parametric hazard models to investigate how mortality risks varied over the first year on ART in human immunodeficiency virus–infected adults (aged 18–73 years) and children (aged 4 months to 15 years) in 2 trials in Zimbabwe and Uganda.

Results. One hundred seventy-nine of 3316 (5.4%) adults and 39 of 1199 (3.3%) children died; half of adult/pediatric deaths occurred in the first 3 months. Mortality variation over year 1 was similar; at all CD4 counts/CD4%, mortality risk was greatest between days 30 and 50, declined rapidly to day 180, then declined more slowly. One-year mortality after initiating ART with 0–49, 50–99 or ≥100 CD4 cells/μL was 9.4%, 4.5%, and 2.9%, respectively, in adults, and 10.1%, 4.4%, and 1.3%, respectively, in children aged 4–15 years. Mortality in children aged 4 months to 3 years initiating ART in equivalent CD4% strata was also similar (0%–4%: 9.1%; 5%–9%: 4.5%; ≥10%: 2.8%). Only 10 of 179 (6%) adult deaths and 1 of 39 (3%) child deaths were probably medication-related. The most common cause of death was septicemia/meningitis in adults (20%, median 76 days) and children (36%, median 79 days); pneumonia also commonly caused child deaths (28%, median 41 days).

Conclusions. Children ≥4 years and adults with low CD4 values have remarkably similar, and high, mortality risks in the first 3 months after ART initiation in low-income countries, similar to cohorts of untreated individuals. Bacterial infections are a major cause of death in both adults and children; targeted interventions could have important benefits.
mortality declined from 9% to 6% during 2002–2007 as the median pre-ART CD4 count increased from 69 to 113 cells/μL. Nevertheless, early mortality remained approximately 6-fold higher in those initiating ART with CD4 <50 cells/μL vs >200 cells/μL even in the latest period [4].

Although 2010 World Health Organization (WHO) guidelines recommend ART at a CD4 count threshold of <350 cells/μL [6], patients continue to present with low CD4 counts or to refuse ART at higher CD4 counts [7]. If only 15% of the 7.5 million untreated HIV-infected persons in need [1] have CD4 <50 cells/μL and experience 7% early mortality, this corresponds to 78,750 deaths in this subgroup alone. However, few data inform how excess early mortality might be reduced [8]. While several adult studies have demonstrated substantial declines in mortality risk on ART [2, 9–13], time has been variably and arbitrarily categorized [14], preventing precise exploration of how mortality risk changes following ART initiation. Furthermore, few studies have addressed this question in children, and only 1 study has compared mortality risks with those of adults [15]. We therefore investigated how mortality risk changed over time in adults and children starting ART, using flexible statistical models for these risks, and explored possible reasons that might inform rational interventions. We used pooled data from 2 large African adult and pediatric trials of ART management strategies, in which mortality ascertainment was near complete.

**METHODS**

Mortality during the first year on ART was estimated in HIV-infected adults (aged 18–73 years) and children (aged 4 months to 15 years) enrolled in the Development of Antiretroviral Therapy in Africa (DART) [16] and Antiretroviral Research for Watoto (ARROW; www.arrowtrial.org) trials, respectively. Both trials recruited previously untreated individuals (except to prevent mother-to-child-transmission) from 3 centers in Uganda and 1 in Zimbabwe. In DART, adults had a CD4 count <200 cells/μL and symptomatic (WHO stage 2/3/4) HIV disease; children in ARROW met WHO 2006 pediatric guidelines for ART [17] due to immunosuppression (age <12 months: CD4% <25%; age 1 to <3 years: <20%; age 3 to <5 years: <15% [or CD4 <350 cells/μL]; age ≥5 years: <15% [or CD4 <200 cells/μL]) and/or WHO 3/4 stage disease.

The primary randomized comparison in both trials was clinically driven monitoring (CDM) vs routine laboratory plus clinical monitoring (LCM) for toxicity (hematology/biochemistry) and efficacy (CD4 counts); no real-time HIV loads were assayed. As there was no evidence of mortality or disease progression differences between randomized groups during the first 2 years in DART [16], and no plausible mechanism for early differences in mortality other than toxicity-related deaths (see Results below), groups were pooled for analysis of 12-month mortality on ART; subsequent deaths and follow-up were censored at this time point. At enrollment in 2003–2004, DART participants received 3-drug ART (coformulated zidovudine/lamivudine plus tenofovir, abacavir, or nevirapine), open-label except for 600 participants randomized to abacavir vs nevirapine [18]. In 2007–2008, ARROW participants received open-label 3- or 4-drug ART (abacavir/lamivudine plus a nonnucleoside reverse transcriptase inhibitor [NNRTI] or zidovudine + NNRTI); participants starting 4 drugs reduced to 3 drugs at 36 weeks.

Participants in both studies saw a doctor and underwent full blood count, lymphocyte subset (CD4, CD8), and biochemistry testing (bilirubin, urea, creatinine, alanine aminotransferase, and aspartate aminotransferase) every 12 weeks; they were reviewed by a nurse using a standard symptom checklist every 4 weeks. All LCM results were returned to clinicians, whereas CDM results were only returned if requested for clinical reasons (not CD4) or grade 4 laboratory toxicity. For all participants, diagnostic investigations and other tests (except CD4/lymphocytes for CDM) could be requested, concomitant medications prescribed, and antiretrovirals substituted for adverse events. Switching for “failure” before 48 weeks was discouraged [17, 19]. In both trials, participants missing visits were contacted by phone or by fieldworker visit. All reported WHO stage 4 events and deaths were reviewed by an endpoint review committee (ERC) with independent chair and members, who assigned cause of death blinded to randomization.

To estimate a continuously varying death rate (hazard), we used flexible parametric models [20, 21] counting time from ART initiation to earliest of death, loss to follow-up, or 1 year (see Supplementary Methods). Pre-ART CD4 was categorized by absolute CD4 counts in participants aged ≥4 years and CD4 cell percentage (CD4%) in those aged <4 years, given similar predictive ability of CD4 in untreated children aged ≥4 years and adults [22, 23]. Prespecified categories were 0–49 cells/μL or 0%–4%; 50–99 cells/μL or 5%–9%; 100–149 cells/μL or 10%–14%; and ≥150 cells/μL or ≥15%. The impact of CD4/CD4%, age, sex, WHO stage, and cotrimoxazole at ART initiation was investigated in multivariable models. A second multivariable model also included pre-ART hemoglobin and body mass index (BMI) converted into BMI-for-age z scores following WHO guidelines [24, 25]. Norms at 19 years were used for adults (z score = 0 at BMI = 22.2 [men] and 21.4 [women]). Incidence of different causes of death were compared between adults and children using cause-specific hazards (competing risk subhazards [26] were similar, data not shown). Exact tests were used where no child deaths meant these could not be estimated. All analyses were performed using Stata software version 11.2.
A total of 3316 adults (aged 18–73 years) and 1206 children (aged 4 months to 17 years) initiated ART in DART and ARROW, respectively, in the same Zimbabwean/Ugandan centers. As there were few older adolescents, participants aged 16–17 years (n = 7) were excluded from analysis. More adults than children had severe immunodeficiency (Table 1), likely reflecting earlier accrual (2003–2004 vs 2007–2008) and more stringent DART eligibility criteria of CD4 <200 cells/μL and symptomatic HIV disease. Of 428 children aged 4–15 years with CD4 ≥200 cells/μL, 46% had <350 cells/μL and 48% had a CD4% of <15%, reflecting some discrepancies between CD4/CD4% in children [23]; remaining children with neither (36%) initiated ART for WHO 3/4 events.

Thirty-eight (1.1%) adults and 9 (0.8%) children had unknown vital status at 1 year. In contrast to many programs [27], pre-ART CD4 counts were similar between those lost to follow-up and those followed up at 1 year (adults: median 117 vs 88 cells/μL, \( P = .26 \) [vs 33 cells/μL among deaths in year 1]; children: 501 vs 368 cells/μL, \( P = .30 \) [vs 103 cells/μL among deaths in year 1]). Participants lost to follow-up were therefore censored.

Table 1. Characteristics at Antiretroviral Therapy Initiation

| Factor | DART (N = 3316) | ARROW 4–15 y (n = 738) | ARROW 0–3 y (n = 461) |
|--------|----------------|------------------------|------------------------|
| Center |                |                        |                        |
| Entebbe, Uganda | 1020 (31%) | 135 (18%) | 52 (11%) |
| IDI/PIDC, Uganda | 300 (9%) | 194 (26%) | 118 (26%) |
| JCRC, Uganda | 997 (30%) | 286 (39%) | 114 (25%) |
| Harare, Zimbabwe | 999 (30%) | 123 (17%) | 177 (38%) |
| Women/girls | 2156 (65%) | 369 (50%) | 236 (51%) |
| Age, y | 36 (31–42) | 8 (6–10) | 1 (1–2) |
| Pre-ART CD4, cells/μL | 86 (21–139) | 251 (95–398) | 726 (471–1081) |
| 0–49 (0%–4% if <4 y) | 1109 (33%) | 131 (18%) | 27 (6%) |
| 50–99 (5%–9% if <4 y) | 785 (24%) | 56 (8%) | 87 (19%) |
| 100–149 (10%–14% if <4 y) | 759 (23%) | 52 (7%) | 128 (28%) |
| 150–199 (15%–19% if <4 y) | 663 (20%) | 71 (10%) | 98 (21%) |
| ≥200 (≥20% if <4 y) | 0 | 428 (58%) | 121 (26%) |
| WHO stage |                |                        |                        |
| 1/2 | 673 (20%) | 214 (29%) | 136 (30%) |
| 3 | 1864 (56%) | 444 (60%) | 235 (51%) |
| 4 | 779 (23%) | 80 (11%) | 90 (20%) |
| Weight, kg | 57 (50–64) | 20 (17–26) | 9 (7–11) |
| BMI, kg/m² | 21.1 (19.1–23.6) | 15.0 (14.0–15.9) | 15.6 (14.2–16.7) |
| BMI-for-age z score (WHO⁵) | −0.2 (−1.0 to 0.6) | −0.8 (−1.5 to −0.1) | −0.2 (−1.6 to 0.7) |
| Hemoglobin, g/dL | 11.4 (10.3–12.7) | 11.1 (10.2–11.9) | 9.9 (9.2–10.7) |
| On cotrimoxazole prophylaxis | 2048⁶ (62%) | 735⁷ (99.6%) | 460⁸ (99.8%) |
| First ART regimen |                |                        |                        |
| ZDV/3TC/TDF | 2469 (74%) | 0 | 0 |
| ZDV/3TC/ABC | 300 (9%) | 0 | 0 |
| ZDV/3TC/NVP | 547 (16%) | 0 | 0 |
| 3TC/ABC/EFV | 0 | 128 (17%) | 11² (2%) |
| 3TC/ABC/NVP | 0 | 111 (15%) | 143 (31%) |
| ZDV/3TC/ABC/EFV | 0 | 284 (38%) | 19⁹ (4%) |
| ZDV/3TC/ABC/NVP | 0 | 215 (29%) | 288 (62%) |

Data are presented as No. (%) or median (interquartile range). Weight and BMI not available pre-ART for 23 and 33 DART participants, respectively.

Abbreviations: 3TC, lamivudine; ABC, abacavir; ARROW, Antiretroviral Research for Watoto; ART, antiretroviral therapy; BMI, body mass index; DART, Development of Antiretroviral Therapy in Africa; EFV, efavirenz; IDI/PIDC, Infectious Diseases Institute/Pediatric Infectious Diseases Clinic (Mulago Hospital); JCRC, Joint Clinical Research Center; NVP, nevirapine; TDF, tenofovir; WHO, World Health Organization; ZDV, zidovudine.

a All DART participants had CD4 <200 cells/μL at ART initiation as trial entry criterion.

b For adults, calculated using WHO references [24], assuming age 19 years.

c In addition, 3 (0.1%) adults and 3 (0.4%) older children were taking dapsone prophylaxis at ART initiation.

d One child had grade 2 neutropenia at ARROW enrollment and initiated cotrimoxazole 4 months later.

e No dosing available for EFV in children <3 years of age or <15 kg.

RESULTS

A total of 3316 adults (aged 18–73 years) and 1206 children (aged 4 months to 17 years) initiated ART in DART and ARROW, respectively, in the same Zimbabwean/Ugandan centers. As there were few older adolescents, participants aged 16–17 years (n = 7) were excluded from analysis. More adults than children had severe immunodeficiency (Table 1), likely reflecting earlier accrual (2003–2004 vs 2007–2008) and more stringent DART eligibility criteria of CD4 <200 cells/μL and symptomatic HIV disease. Of 428 children aged 4–15 years

with CD4 ≥200 cells/μL, 46% had <350 cells/μL and 48% had a CD4% of <15%, reflecting some discrepancies between CD4/CD4% in children [23]; remaining children with neither (36%) initiated ART for WHO 3/4 events.

Thirty-eight (1.1%) adults and 9 (0.8%) children had unknown vital status at 1 year. In contrast to many programs [27], pre-ART CD4 counts were similar between those lost to follow-up and those followed up at 1 year (adults: median 117 vs 88 cells/μL, \( P = .26 \) [vs 33 cells/μL among deaths in year 1]; children: 501 vs 368 cells/μL, \( P = .30 \) [vs 103 cells/μL among deaths in year 1]). Participants lost to follow-up were therefore censored.

HIV/AIDS • CID 2012:55 (15 December) • 1709
at last clinic attendance (median 26 weeks [adults] and 20 weeks [children]). Eleven (0.3%) adults and 3 (0.3%) children switched to second-line ART (all but 1 adult >46 weeks).

Overall, 179 (5.4%) adults and 39 (3.3%) children died in the first year following initiation of ART. As expected, mortality varied strongly with pre-ART CD4 ($P < .0001$ for adults and older children), with no statistical evidence of variation in younger children ($P = .70$). Interestingly, mortality risk was similar in adults and older children ($\geq 4$ years) in the same CD4 strata (Figure 1). Risk was also similar in younger children (<4 years) in parallel CD4% strata, although power was low to detect genuine differences. Results were similar with a 5-year threshold [19] and in older children with CD4 <350 cells/µL (data not shown). Risk gradients were much stronger <100 cells/µL (or <10% for age <4 years); above this, differences were smaller with no evidence supporting important variation ($P > .6$). Subsequent analyses therefore pooled CD4 >100 cells/µL.

Figure 2 shows how mortality risk varies day-by-day over the first year on ART. At all CD4/CD4%, and in adults and children, mortality risk increased from enrollment to a maximum between 30 and 50 days after ART initiation, declined rapidly to 180 days, then declined more slowly. In both adults and children, half and three-quarters of the deaths occurred in the first 3 and 6 months, respectively. The sharp initial risk increase is likely because of trial consent (excluding moribund patients); the earliest deaths occurred on day 8 (DART) and day 16 (ARROW). In sensitivity analyses, assuming the 1% of participants lost to follow-up had died, differences between groups were similar. Pooling data from adults and children, there was no evidence for a differential effect of pre-ART CD4 with age (heterogeneity $P = .95$ [0–49 cells/µL, 0%–4%; $P = .98$ [50–99 cells/µL, 5%–9%; and $P = .15$ [≥100 cells/µL, ≥10%]).

Adjusting for CD4/CD4%, mortality risks were lower in those with earlier pre-ART WHO stage or on cotrimoxazole at ART initiation ($P < .0001$), but there was no evidence of additional effects of age, sex, or center ($P > .16$; Supplementary Table 1). After adjusting for increased mortality risk with lower pre-ART hemoglobin and BMI ($P < .0001$), there was weak evidence of slightly increased mortality risk in older individuals on ART ($P = .02$).

There was no evidence supporting a large contribution of ART (or other drug) toxicity to mortality on ART during the first 3 months or the first year (Table 2). Only 6% of adult and 3% of child year-1 deaths were ERC-adjudicated as primarily medication-related (4% and 3% primarily ART-related, respectively; Table 2). ART-related deaths were from septicaemia (4 adults, 1 child), neutropenia without sepsis (2 adults), anemia (1 adult), and hepatitis (1 adult). Sixty percent of primarily medication-related deaths occurred in those with pre-ART CD4 <50 cells/µL, similar to deaths that were uncertainly medication-related (62%) and primarily HIV-related (68%).

![Figure 1. Kaplan-Meier mortality 1 year after antiretroviral therapy (ART) initiation according to age and pre-ART CD4 count. Abbreviations: ART, antiretroviral therapy; ARROW, Antiretroviral Research for Watoto; DART, Development of Antiretroviral Therapy in Africa.](https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cis171)
A large range of causes of death was observed in adults and children, the most common being septicemia/meningitis, with pneumonia also a common child cause of death (Table 2). Causes of death in the first 3 months were similar to the first year overall. Organisms were identified in relatively few cases but were typical for the setting, including *Streptococcus pneumoniae*, *Escherichia coli*, *Staphylococcus aureus*, and *Klebsiella pneumoniae*. Cryptococcus accounted for 11% of adult deaths, but no child deaths (exact \(P = .03\) vs noncryptococcal cause); tuberculosis accounted for 8% vs 3% of deaths, respectively (adjusted \(P = .25\)). The only strong evidence for differing incidence of death between adults and children was from pneumonia (4.72-fold higher risk in children, \(P = .001\); 3.73-fold higher risk pooling all respiratory-related deaths, \(P = .002\)). Uncertain or unlikely relationship to HIV/drugs and uncertain cause of death tended to be reported less frequently in children (adjusted \(P = .04, .08,\) and .09, respectively). Of causes with \(\geq 10\) adult deaths, the earliest were from pneumonia (median 34 days on ART), then cryptococcal disease (median 50 days), tuberculosis (median 72 days), septicemia/meningitis (median 76 days), other severe brain disease (median 88 days), and unknown causes (median 117 days). Child deaths from pneumonia and septicemia/meningitis occurred at similar timescales (median 41 and 79 days, respectively).

One question is whether high early mortality risks merely reflected carryover effects of late presentation, with a delay in ART effectiveness in those with low pre-ART CD4 counts. We therefore estimated mortality risks over the first year after enrollment in adults with CD4 <200 cells/\(\mu\)L in the Entebbe cohort [28] and children in the 3Cs4kids cohort collaboration [29] who presented for care with low CD4 but did not receive ART, using the same CD4 strata and models as above (see Supplementary Methods for cohort details).

Without ART, 40% (206/514) of adults and 9% (126/1377) of children died during the first year after enrollment; no adults, but 451 (33%) children, actually initiated ART during this first year and were censored. Figure 3 shows that high mortality risks were similar in the first 30 days after enrollment to early risks on ART. Without ART, risks remained high, particularly for adults, whereas those starting ART experienced rapid drops in risk.
Table 2. Causes of Death in the First Year on Antiretroviral Therapy

| Relationship to HIV and drugs | DART 18–73 y (n = 179) | ARROW 4 mo to 15 y (n = 39) | Crude Cause-Specific (ARROW:DART) HR (95% CI), P Value | Adjusted\(^a\) Cause-Specific (ARROW:DART) HR (95% CI), P Value | Median (IQR) d From ART Initiation to Death | Deaths Within 3 mo of ART Initiation |
|------------------------------|------------------------|-----------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------------------------|-------------------------------------|
| Relationship to HIV and drugs |                        |                             |                                                      |                                                      | DART\(^b\)                             | ARROW\(^b\)                          |
| Primarily HIV related        | 92 (51%)               | 28 (72%)                    | .83 (.54–1.27), .39                                  | 1.34 (.86–2.09), .19                                  | 69 (32–160)                             | 86 (42–153)                          |
| Primarily medication related | 10\(^d\) (6%)          | 1\(^d\) (3%)                | .27 (.04–2.14), .22                                  | .43 (.05–3.54), .44                                    | 53 (25–75)                             | 39 (29–47)                          |
| Uncertain whether primarily HIV or medication related | 24\(^e\) (13%)         | 5\(^e\) (13%)               | .57 (.22–1.49), .25                                  | .91 (.34–2.47), .85                                    | 81 (47–128)                            | ...                                 |
| Cause of death               |                        |                             |                                                      |                                                      |                                        |                                     |
| Septicemia/meningitis\(^g\) | 36 (20%)               | 14 (36%)                    | 1.06 (.57–1.97), .84                                  | 1.50 (.78–2.86), .22                                   | 76 (39–136)                             | 79 (51–126)                         |
| Unknown cause\(^h\)          | 33 (18%)               | 3 (8%)                      | .25 (.08–.81), .02                                    | .35 (.10–1.16), .09                                     | 117 (47–207)                           | 128 (107–205)                       |
| Extrapulmonary cryptococcosis| 20\(^f\) (11%)         | 1 (3%)                      | ...                                                   | ...                                                   | 50 (28–109)                            | ...                                 |
| Other non-WHO stage 4 brain disease | 16\(^i\) (9%)     | 0                           | ...                                                   | ...                                                   | 88 (56–188)                            | ...                                 |
| Tuberculosis                  | 14 (8%)                | 1 (3%)                      | .19 (.03–1.48), .11                                   | .29 (.04–2.32), .25                                    | 72 (36–143)                            | ...                                 |
| Pulmonary                     | 9 (5%)                 | 0                           | ...                                                   | ...                                                   | 6 (7%)                                 | 0                                   |
| Extrapulmonary                | 5 (3%)                 | 1 (3%)                      | ...                                                   | ...                                                   | 2 (2%)                                 | 0                                   |
| Pneumonia\(^j\)              | 10 (6%)                | 11 (28%)                    | 3.01 (1.28–7.09), .01                                  | 4.72 (1.91–11.7), .001                                  | 34 (28–274)                            | 41 (29–138)                        |
| Other WHO 4 OIs (toxoplasmosis, PCP, CMV, cryptosporidiosis, isosporiasis) | 8 (4%)                 | 1 (3%)                      | .34 (.04–2.74), .31                                    | .67 (.08–5.66), .72                                    | 49 (40–88)                             | ...                                 |
| Wasting, diarrhea, gastrointestinal | 6 (3%)               | 3 (8%)                      | 1.36 (.34–5.45), .66                                  | 2.83 (.68–11.8), .15                                   | 171 (69–283)                           | 100 (39–107)                       |
| AIDS-defining malignancy (KS, lymphoma) | 6 (3%)                 | 0                           | ...                                                   | ...                                                   | 179 (119–206)                          | 0                                   |
| Anemia, neutropenia, thrombocytopenia without sepsis | 6 (3%)                 | 0                           | ...                                                   | ...                                                   | 78 (59–102)                            | ...                                 |
| Hepatic                      | 6 (3%)                 | 0                           | ...                                                   | ...                                                   | 212 (75–339)                           | 2 (2%)                              |
| Trauma, obstetric, suicide   | 6 (3%)                 | 1 (3%)                      | .45 (.05–3.76), .46                                    | .30 (.04–2.48), .26                                    | 195 (181–216)                          | ...                                 |
| Other lung disease            | 2\(^e\) (2%)           | 0                           | ...                                                   | ...                                                   | 95 (81–141)                            | 1 (1%)                              |
| Malaria                      | 2 (1%)                 | 1 (3%)                      | ...                                                   | ...                                                   | ...                                   | 1 (1%)                              |
## Table 2 continued.

| Cause | Median (IQR) d From ART Initiation to Death | Deaths Within 3 mo of ART Initiation |
|-------|--------------------------------------------|--------------------------------------|
|       | DARTb | ARROWb | DART | ARROW |
| Renal (non-AIDS) | 2 (1%) | 0 | 0 | 0 |
| Cerebrovascular disease | 0 | 3 (8%) | 3 (3%) | 0 |
| Other single causes in either trial | 5 (2%) | 1 (3%) | 0 | 0 |

Abbreviations: ART, antiretroviral therapy; ARROW, Antiretroviral Research for Watoto; CI, confidence interval; CMV, cytomegalovirus; DART, Development of Antiretroviral Therapy in Africa; HIV, human immunodeficiency virus; HR, hazard ratio; IQR, interquartile range; KS, Kaposi sarcoma; OI, opportunistic infection; PCP, pneumocystis pneumonia; WHO, World Health Organization.

a Adjusted for CD4/CD4% categories (0–49 cells/μL, 0%–4%; 50–99 cells/μL, 5%–9%; ≥100 cells/μL, ≥10%). Sub-hazard ratios corresponding to the cumulative incidence [26] were similar (data not shown).

b For groups with 3 or more deaths.

c Eight primarily ART related: 7 zidovudine (1 alone, 2 + cotrimoxazole, 2 + tenofovir, 1 + sulphadiazine/pyrimethamine, 1 + sulphamethoxazole), 1 nevirapine; 2 primarily other medication related only: 1 rifampicin/isoniazid/ethambutol/pyrazinamide, 1 dapsone.

d Primarily ART related: zidovudine + cloxacillin + ceftriaxone.

e Twenty-four uncertain whether primarily ART related (or HIV related): 21 zidovudine (12 alone, 3 + cotrimoxazole, 1 + tenofovir, 1 + tenofovir + amoxicillin + paracetamol, 1 + tenofovir + ciprofloxacin + diclofenac, 1 + tenofovir + dexamethasone + carbamazepine, 1 + tenofovir + rifampicin + isoniazid, 1 + tenofovir + rifampicin + isoniazid + ethambutol + pyrazinamide + ceftriaxone), 2 nevirapine, 1 stavudine; 1 uncertain whether primarily other medication related (or HIV related): 1 fluconazole.

f Four uncertain whether primarily ART related (or HIV related): 4 zidovudine (2 alone, 2 + cotrimoxazole); 1 uncertain whether primarily other medication related (or HIV related): cotrimoxazole.

g Organisms isolated from bacterial infections (blood cultures unless stated: DART: Streptococcus pneumoniae (3), Escherichia coli (4, plus 1 with urinary E. coli only), Staphylococcus aureus (2). ARROW: S. pneumoniae (3), S. aureus (1), Pseudomonas aeruginosa (1), Klebsiella pneumoniae + Enterococcus spp (1), plus 1 with urinary K. pneumoniae only and 1 with Salmonella spp isolated from stool.

h Primary cause of death could not be determined (eg, because the patient died at home or presented very sick without time for diagnostic tests).

i Nineteen cryptococcal meningitis, 1 cryptococcemia.

j Participant fulfilled clinical criteria for at least 1 of cerebral toxoplasmosis, cryptococcal meningitis, tuberculosis meningitis, or progressive multifocal leukoencephalopathy, but no diagnostic tests were done and/or the patient failed to respond to first-line treatment and died without further investigations.

k 2 pulmonary embolus; 1 chronic obstructive pulmonary disease.

l Glomerulonephritis, chronic renal failure in a patient with type 1 diabetes and hypertension.

m Stevens-Johnson syndrome, diabetes, lactic acidosis, non-AIDS cancer (carcinomatosis), cardiomyopathy.

n HIV encephalopathy.
DISCUSSION

Although the substantial benefits of ART are clear, it remains uncertain how best to reduce excess early mortality in severely immunocompromised HIV-infected individuals initiating ART in low-income countries [2, 4]. Our main finding is that patterns of changing mortality risk in the first year on ART are indistinguishable in adults and children ≥4 years; both experience similarly high mortality risks in the first 3 months on ART if they have low pre-ART CD4 counts. Children aged <4 years with low CD4% are at similarly high risk for mortality. Nevertheless and importantly, risks on ART are lower than mortality risks without ART. While earlier HIV diagnosis and prompt ART initiation remain key goals, similarities between adults and children call for interventions to target reductions in early mortality in both; simplification and harmonization of management approaches across both groups would be an advantage in most resource-limited settings. Our findings contrast with the only comparison of early mortality in adults and children to date, which suggested somewhat lower overall risks over the first year on ART in 2- to 14-year-olds entering the Malawi national ART program [15]; however, data on CD4, which is the key determinant of early mortality, were not available.

In addition to comparing mortality risks in adults and children, we also examined potential mechanisms for increased early mortality to inform future interventions. Possible reasons for an early limited increase in mortality risk after ART initiation include ART toxicity, immune reconstitution inflammatory syndrome (IRIS), or time required for ART to become effective. Our study does not support a major role of ART toxicity; although a small number of deaths were adjudicated as primarily drug-related (mainly to zidovudine [anemia/neutropenia/sepsis] and nevirapine [hepatic failure]), participants initiating ART with low CD4 counts suffered disproportionately from both drug- and HIV-related deaths, suggesting that advanced immunodeficiency at ART initiation, rather than ART alone, played a role in toxicity-related deaths [30]. We did not directly assess the contribution of...
IRIS because these clinical criteria were not systematically recorded in 2003–2004, when the early deaths occurred in DART. It is pertinent that, even if IRIS was a mechanism, early mortality risks on ART were no greater than observed in similar groups without ART. This supports recent trial findings that, despite increased IRIS, early ART significantly reduced mortality in patients with advanced HIV disease and tuberculosis [31, 32]. The fact that mortality risks in the first weeks on ART were similar to those without ART might also suggest that pre-ART risks persist until ART reaches maximal effectiveness. If this were the case, then increasing ART potency (eg, by adding an integrase inhibitor to initial ART) might benefit patients with advanced immunodeficiency. Integrase inhibitors are obvious candidates for such induction-maintenance strategies as they achieve the most rapid viral load declines [33].

The diverse early causes of death observed in adults and children present a challenge in selecting interventions targeting specific causes. Although certain opportunistic infections (cryptococcus, tuberculosis) made clear contributions, individually their effects were modest, similar to findings from other studies in adults [34]. Although no child died from cryptococcal disease, this is probably owing to low numbers, as deaths have been reported in older children [35–37]. Our findings suggest that any augmented prophylaxis approach to reduce early morbidity/mortality needs to cover multiple organisms. Although fluconazole [38], isoniazid [39], and cotrimoxazole [40, 41] prophylaxes have important benefits, it remains unclear whether toxicity risks associated with simultaneous initiation with 3-drug (or 4-drug) ART would outweigh any potential advantages in patients presenting with very low CD4 counts. Aside from toxicity concerns, the considerably increased pill burden and potential for drug–drug interactions suggests that such strategies need formal evaluation.

Invasive bacterial infections (septicemia/meningitis/pneumonia) were the commonest cause of death in adults and children. Similarly high contributions of bacterial infections to early mortality on ART were described in a comparison of adult cohorts in Brazil and the United States [42]. In contrast to tuberculosis and cryptococcal disease, little attention has been paid to this finding in the wider literature, although septicemia and pneumonia were relatively commonly reported as “other” cause of death in a recent meta-analysis of 1-year mortality in adults [34] and the importance of bacterial infections in child mortality has been noted [43]. Cotrimoxazole prophylaxis, received by all ARROW children and 62% DART adults at ART initiation, has major mortality benefits in HIV-infected persons [40, 41], presumed to occur through reduction of bacterial infections. Given high rates of cotrimoxazole resistance, our data suggest that additional broad-spectrum antibiotic prophylaxis might also improve outcomes among adults and children presenting with low CD4 counts.

As previously reported [12, 34, 44], low BMI and hemoglobin were associated with higher early mortality in adults and children in our study. Of note, BMI associations were present even with mildly abnormal BMI, suggesting a potential role for additional nutritional supplementation in reducing early mortality following ART initiation [45]. This approach could improve drug absorption, known to be impaired in severe HIV disease, and possibly adherence, as many patients report feeling acute hunger after starting ART [46], probably reflecting a profound catabolic state induced by severe HIV infection, which abruptly reverses with ART. However, moderately sized trials in HIV-infected adults [47] and in patients with tuberculosis [48] starting treatment with severe malnutrition (BMI <18.5) have shown no significant effect of ready-to-eat and fortified soya foods on mortality, although early weight, BMI, and CD4 gains were observed. Therefore, the role of supplementation in reducing early mortality in those without severe malnutrition remains unclear.

Our trial data have 3 major advantages over previous studies for investigating early mortality. First, vital status was accurately and completely ascertained in contrast to most programs [27, 34], thus limiting the impact of mortality misclassification. Even the assumption that all those lost to follow-up in the first year had died (1.1% adults, 0.8% children) did not alter results. Second, causes of death were assigned by an independent committee, based on a structured narrative and without knowledge of the randomized group or CD4 (part of the randomizations). Third, we used innovative flexible parametric models to directly assess how mortality risk changed over time on ART. The alternative strategy, categorizing time on ART [2, 10–13, 15, 43, 49, 50], produces risk estimates that change abruptly, making them biologically implausible [14], and may poorly represent the underlying data. In recognition of this problem, 2 recent papers used a piecewise Weibull model (which nevertheless makes strong assumptions about changing risks) [9] or smoothed hazards from semi-parametric Cox models [51].

WHO guidelines advocate ART initiation in HIV-infected adults and children aged ≥5 years at a CD4 count of <350 cells/μL [6], but substantial numbers of individuals continue to present for care late in HIV infection [7, 52–54]. Given experiences in high-income countries [55, 56], late presentation will continue in ART programs for the foreseeable future. However, the consequences of such late presentation, in terms of early morbidity/mortality on ART, are far more severe in low-income settings. To maximize ART benefits, it is essential to identify which, if any, interventions could reduce high early death rates if given with ART. Recent experiences in a trial of hydroxychloroquine, which significantly increased HIV viral load in ART-naive patients despite being expected to reduce immune activation [57], demonstrate the importance of
testing potential interventions in randomized controlled trials. Our findings do not identify any single plausible mechanism; rather, they suggest that anti-HIV, anti-infection (or enhanced prophylaxis), and anti-malnutrition/malabsorption may all be important potential approaches. The REALITY trial (ISRCTN43622374) plans to address these questions in adults and older children in a $2 \times 2 \times 2$ factorial design from 2012. Our findings also demonstrate strong similarities in early mortality patterns between adults and children. Where the same health providers treat both age groups, as in most of sub-Saharan Africa, integrating research will likely provide the most relevant evidence base for future management.

**Supplementary Data**

Supplementary materials are available at *Clinical Infectious Diseases* online (http://www.oxfordjournals.org/our_journals/cid/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

**Notes**

*Acknowledgments.* We thank all the participants and staff from all the centers participating in the Development of Antiretroviral Therapy in Africa (DART) and Antiretroviral Research for Watoto (ARROW) trials.

**DART Trial:**

MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda. H. Grosskurth, P. Munderi, G. Kabuye, D. Nsibambi, R. Kasirye, E. Zalwango, M. Nakazibwe, B. Kikaire, G. Nasuna, R. Massa, K. Fadhifu, M. Namyalo, A. Zalwango, L. Generous, P. Kauka, N. Rutikarayo, W. Nakahima, A. Mugisha, J. Todd, J. Levin, S. Muyingo, A. Ruberantwari, P. Kaleebu, D. Yirrell, N. Ndembí, F. Lyagoba, P. Hughes, M. Aber, A. Medina Lara, S. Foster, J. Amurwon, B. Nyanzi Wakholi, J. Whithrow, K. Wangati, B. Amuron, D. Kajungu, J. Nakiyingi, W. Omony, K. Fadhifu, D. Nsibambi, P. Kauka.

**Joint Clinical Research Centre, Kampala, Uganda.** P. Mugyenyi, C. Kityo, F. Ssali, D. Tumukunde, T. Otím, J. Kabanda, H. Musana, J. Akao, H. Kyomugisha, A. Byamukama, J. Sabiti, J. Karamunyera, P. Pavamunno, S. Mukibi, A. Drasiku, R. Byaruhanga, O. Labeja, P. Katundu, S. Tugume, P. Awojo, A. Namazizi, G. T. Bakeinyyaga, H. Katabira, D. Abaine, J. Tukamushaba, W. Anywar, W. Ojiambo, E. Angweng, S. Murungi, W. Haguna, S. Atwine, J. Kigozi, L. Namale, A. Mukebe, G. Mulindwa, D. Atwiine, A. Muhewezi, I. Nemwesiga, G. Barungi, J. Takubwa, S. Murungi, D. Mwebesa, G. Kagina, M. Mulindwa, F. Ahimbishisere, P. Mweesigwa, S. Akuma, C. Zawedde, D. Nyiragihuriza, C. Tumusime, L. Bagaya, W. Namara, J. Kigozi, J. Karungi, R. Kankunda, R. Enzama.

**University of Zimbabwe, Harare, Zimbabwe.** A. Latifi, J. Hakim, V. Robertson, A. Reid, E. Chidziva, R. Bulaya-Tembo, G. Musoro, F. Taziwa, C. Chimbedze, L. Chakonza, A. Mwaura, C. Muirirvi, G. Tinago, P. Ssowapanasid, M. Simango, O. Chirema, J. Machingura, S. Mutsai, M. Phiri, T. Bafana, M. Chirara, L. Muchabaiwa, M. Muzambi, J. Mutowo, T. Chivhunga, E. Chigvedere, M. Pascoe, C. Wambawba, E. Zengeza, F. Mapinge, S. Makota, A. Jamu, N. Ngormia, H. Chirairo, S. Chitsungo, J. Chimanzí, C. Mweni, R. Warara, M. Matongo, S. Mudzwingwa, M. Jangano, K. Myojo, L. Vere, N. Mdege, I. Machingura.

**Infectious Diseases Institute (formerly the Academic Alliance), Makerere University, Mulago, Uganda.** E. Katabira, A. Ronald, A. Kambungu, F. Lutuwa, I. Mambule, A. Nanfuka, J. Waisambo, E. Nankabambe, R. Naluminya, T. Namuli, R. Kulume, I. Namata, L. Nyachwo, A. Florence, A. Kusiima, E. Lutuwa, R. Nairuha, F. Oketta, E. Buluma, R. Waita, H. Ojiambo, F. Sadik, I. Wanyama, P. Nabongo, J. Ouygi, F. Sematala, A. Muneegi, C. Twijule, H. Byakwaga.

**The AIDS Support Organisation (TASO), Mulago, Kampala, Uganda.** R. Ochai, D. Muhweezi, A. Coutinho, B. Etoikot.

**Imperial College, London, UK.** C. Gilks, K. Boocock, C. Puddephatt, C. Grundy, J. Bohnahan, D. Winogron.

**MRC Clinical Trials Unit, London, UK.** D. M. Gibb, A. Burke, D. Bray, A. Babiker, A. S. Walker, H. Wilkes, M. Rauchenberger, S. Sheehan, C. Spencer-Drake, K. Taylor, M. Spyer, A. Ferrier, B. Naidoo, D. Dunn, R. Goodall, J. H. Darbyshire, L. Petö.

**Independent DART Trial Monitors.** R. Nanfuka, C. Mufuka-Kapuya.

**Trial Steering Committee.** I. Weller (Chair), A. Babiker (Trial Statistician), S. Bahendeka, M. Bassett, A. Chogo Wapakhabulo, J. H. Darbyshire, B. Gazzard, C. Gilks, H. Grosskurth, J. Hakim, A. Latifi, C. Mapuchere, O. Mugarungi, P. Mugyenyi. Observers: C. Burke, S. Jones, C. Newland, G. Pearce, S. Rahim, J. Rooney, M. Smith, W. Snowden, J.-M. Steens.

**Data and Safety Monitoring Committee.** A. Brekenridge (Chair), A. McLaren (previous Chair—deceased), C. Hill, J. Matenga, A. Pozniak, D. Serwadda.

**Endpoint Review Committee.** T. Petö (Chair), A. Palfreeman, M. Borok, E. Katabira.

**ARROW Trial:**

Joint Clinical Research Centre, Kampala, Uganda. P. Mugyenyi, V. Musiime, V. D. Afayo, E. Bagurukira, J. Bwoomezi, J. Byaruhanga, K. Eriu, C. Karungi, H. Kizito, M. Mutumba, W. S. Namala, J. Namusanje, R. Nandugwa, T. K. Nakijuko, E. Natukunda, M. Ndigendawani, S. O. Nsinyona, F. Ondongo, K. Robinah, M. Ssenyonga, D. Seremba, J. Tezizkayabiri, C. S. Tumusime.

**MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.** P. Munderi, P. Nahliraya-Ntge, M. Aber, F. N. Kagga, P. Kaleebu, R. Katuramu, J. H. Kyalimpa, J. Lutaikome, L. Matama, M. Musingizi, G. Nabulime, A. Ruberantwari, R. Sebukeyi, I. M. Sekamte, G. Tushabe, D. Wangi.

**Baylor-Uganda, Paediatric Infectious Disease Centre, Mulago Hospital, Uganda.** A. Kiekitiwina, P. Musoke, S. Bakeera-Kitaka, R. Namuddu, P. Kasirye, J. K. Balungi, A. Babiry, J. Asello, S. Nakalanzani, N. C. Ssemambo, J. Nakafeero, J. N. Kairu, E. K. George, G. Musoba, J. Ssanyu, S. Ssenyonojo.

**University of Zimbabwe, Harare, Zimbabwe.** K. J. Nathoo, M. F. Bwakura-Dangarembizi, F. Mapinge, T. Mhute, T. Vhembo, R. Mandidewa, D. Nyoni, C. Katanda, G. C. Tinago, J. Bhiri, D. Muchabaiwa, S. Mudzingwa, M. M. Chipiti, M. Phiri, J. Steamer, C. C. Marozva, S. J. Maturure, L. Manhatane, S. Tskirikate, G. Tushabe, D. Wangi.

**Medical Research Council Clinical Trials Unit, London, UK.** D. M. Gibb, M. J. Thomason, A. D. Cook, J. M. Crawley, A. A. Ferrier, B. Naidoo, M. J. Spyer, A. S. Walker, L. K. Kendall.

**Independent ARROW Trial Monitors.** R. Nanfuka, I. Machungira.

**Trials Steering Committee.** I. Weller (Chair), E. Luyirika, H. Lyall, E. Malinga, C. Mwansambo, M. Nyathi, A. Wapakhabulo, D. M. Gibb, A. Kiekitiwina, P. Mugyenyi, P. Munderi, K. J. Nathoo. Observers: S. Kim, M. MacNeil, M. Roberts, W. Snowden.

**Data and Safety Monitoring Committee.** A. Brekenridge (Chair), C. Hill, J. Matenga, A. Pozniak, J. Tuwine.

**Endpoint Review Committee.** G. Tudor-Williams (Chair), H. Barigye, H. A. Mijuruz, G. Ndezei.

**Entebbe Cohort:**

MRC Research Unit on AIDS/Uganda Virus Research Institute, Entebbe, Uganda. C. Watera, G. Miio, S. Zawedde, J. Nakiyingi, D. Rutebarika, H. Grosskurth.

---

1Staff that left during the course of the DART trial.
3Ceksids: South Africa. H. Zar, B. Eley, P. Roux, M. Cotton, T. Meyers, H. Moultrie.

Zambia. V. Mulenga, C. Chintu, C. Kankasa.

Cote d’Ivoire. P. Mselati, P. Fassino, N. Elenga.

Malawi. S. Graham, J. Ellis, R. Weigel.

Uganda. C. Giaquinto, M. Nanyonga, E. Morelli, B. Atai.

Brazil. J. Pinto, C. Araújo, A. Carvalho, I. Carvalho, A. Diniz, F. Ferreira, V. Lobato, T. Sanchez.

United Kingdom. T. Duong, D. Dunn, D. M. Gibb, C. Duff.

Author contributions. The DART trial was conducted by P. Muggenyi, P. Munderi, J. H., E. K., and C. K. The ARROW trial was conducted by K. N., A. K., P. Muggenyi, and P. N.-N.; trials were coordinated in the United Kingdom by D. M. G., A. S. W., A. J. P., and C. F. G. In addition, A. S. W. conducted the analyses. A. S. W. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to interpretation of the data. A. S. W. wrote the first draft of the paper with D. M. G. and A. J. P. All authors revised the manuscript critically and approved the final version.

Financial support. The DART trial was supported by the UK Medical Research Council (MRC; grant number G0600344); the UK Department for International Development (DFID); and the Rockefeller Foundation. GlaxoSmithKline, Gilead Sciences, and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott Laboratories provided lopinavir/ritonavir (Kalera/Aluvia) as part of the second-line regimen for DART. The ARROW trial was supported by the UK MRC (grant number G0300400) and the UK DFID. Drugs are provided by GlaxoSmithKline, Gilead Sciences, and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott Laboratories provided lopinavir/ritonavir (Kalera/Aluvia) as part of the second-line regimen for DART. The ARROW trial was supported by the UK MRC (grant number G0300400) and the UK DFID. Drugs are provided by GlaxoSmithKline and the National ART Programmes of Uganda and Zimbabwe.

Potential conflicts of interest. A. S. W. is a board member of Tibotec, and is on the speakers’ bureau of Gilead; D. M. G. is a board member of Tibotec. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2011. Geneva, Switzerland: WHO, 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf. Accessed 18 December 2011.

2. Braithwait P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817–24.

3. Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678–87.

4. Cornwell M, Grimsrud A, Fairall L, et al. Temporal changes in program outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. AIDS 2010; 24:2262–70.

5. Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS One 2010; 5:e13268.

6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.

7. Katz TT, Essien T, Marindu ET, et al. Antiretroviral refusal among newly diagnosed HIV-infected adults in Soweto, South Africa. AIDS 2011; 25:1777–81.

8. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010; 5:18–26.

9. Moore DM, Yiannoutsos CT, Musicik BS, et al. Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2011; 58:289–96.

10. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One 2011; 6: e21795.

11. Zachariah R, Harries K, Moses M, et al. Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi. Trop Med Int Health 2009; 14:713–21.

12. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355–60.

13. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009; 51:615–23.

14. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25:127–41.

15. Weigel R, Estill J, Egger M, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS 2012; 26:365–73.

16. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375:123–31.

17. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006. Available at: http://www.who.int/hiv/pub/guidelines/pediatric2009.pdf. Accessed 17 September 2012.

18. DART Trial Team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 2008; 13:6–16.

19. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.

20. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002; 21:2175–97.

21. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Statata J 2009; 9:265–90.

22. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197:398–404.

23. Boyd K, Dunn DT, Castro H, et al. Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. J Infect Dis 2008; 197:398–404.

24. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007; 85:660–7.

25. World Health Organization. WHO child growth standards: methods and development: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age. Geneva, Switzerland: WHO, 2006.

26. Fene JP, Gray RJ. A proportional hazards model for the redistribution of a competing risk. J Am Stat Assoc 1999; 94:496–509.

27. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009; 4:e5790.

28. Mulder DW, Nunn AJ, Wagner HU, Kamali A, Kenega-Kayondo JF. HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan population cohort. AIDS 1994; 8:87–92.
29. 3C4kids Cohort Collaboration. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2008; 22:97–105.
30. Castelnuovo B, Kiragga A, Kamya MR, Manabe Y. stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr 2011; 59:56–63.
31. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471–81.
32. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482–91.
33. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796–806.
34. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2012; 6:e28691.
35. Gumbo T, Kadzirange G, Mielke J, Gangaidzo IT, Hakim JG. Cryptococcus neoformans meningocerebritis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2002; 21:54–6.
36. Abadi J, Nachman S, Kressel AB, Pirofski L. Cryptococcosis in children with AIDS. Clin Infect Dis 1999; 28:309–13.
37. Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, Walsh TJ. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:796–800.
38. Parkes-Ratanshi R, Kamali A, Wakeham K, et al. Successful primary prevention of cryptococcal disease using fluconazole prophylaxis in HIV-infected Ugandan adults. In: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8–11 February 2009. Abstract 32.
39. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; CD000171.
40. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immuno-suppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375:1278–86.
41. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.
42. Grinsztejn B, Veloso VG, Friedman RK, et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States. AIDS 2009; 23:2107–14.
43. Lumbiganon P, Karimahia A, Aupubh L, et al. Survival of HIV-infected children: a cohort study from the Asia-Pacific region. J Acquir Immune Defic Syndr 2011; 56:365–71.
44. Liu E, Spiegelman D, Senu H, et al. Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. Journal Infect Dis 2011; 204:282–90.
45. Koethe JR, Chi BH, Megazzini KM, Heimburger DC, Stringer JS. Macronutrient supplementation for malnourished HIV-infected adults: a review of the evidence in resource-adequate and resource-constrained settings. Clin Infect Dis 2009; 49:787–98.
46. Nyanzi-Wakholi B, Lara AM, Munderi P, Gilks C. The charms and challenges of antiretroviral therapy in Uganda: the DART experience. AIDS Care 2012; 24:137–42.
47. Ndekha MJ, van Oosterhout JJ, Zijlstra EA, Manary M, Saloojee H, Manary MJ. Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ 2009; 338:b1867.
48. Paton NI, Chua YK, Earnest A, Chee CB. Randomized controlled trial of nutritional supplementation in patients with newly diagnosed tuberculosis and wasting. Am J Clin Nutr 2004; 80:460–5.
49. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298:1888–99.
50. Fenner L, Brinkhof MW, Keiser O, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr 2010; 54:524–32.
51. Hoffmann CJ, Fielding KL, Johnston V, et al. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011; 58:269–76.
52. Parrott FR, Mwafuivwa C, Ngwira B, et al. Combining qualitative and quantitative evidence to determine factors leading to late presentation for antiretroviral therapy in Malawi. PLoS One 2011; 6:e27917.
53. Dickson N, McAllister S, Sharples K, Paul C. Late presentation of HIV infection among adults in New Zealand: 2005–2010. HIV Med 2012; 13:182–9.
54. Zoufaly A, An der Heiden M, Marcus U, et al. Late presentation for antiretroviral therapy at primary health care facilities in Germany. HIV Med 2012; 6:137–8.
55. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010; 15(suppl 1):3–8.
56. Sabin CA, Smith CJ, Youle M, et al. Deaths in the era of HAART 2004–2006. HIV/AIDS 2006; 8:2067–71.
57. Paton N, for the Hydroxychloroquine Trial Team. Effects of hydroxychloroquine on immune activation in ART naïve patients: a 48-week randomised, double-blind, placebo-controlled trial. In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.